Gregory Notte is an Executive Director of Medicinal Chemistry and Research Technologies at Gilead Sciences. Greg leads a team of medicinal chemists primarily focused on discovery of new small molecule drug candidates within oncology and inflammation. In recent years, he’s built out the Research Technologies group, working closely with a cross functional group to identify new drug discovery technologies and platforms, select partners, and foster the success of those external collaborations. Over his 16-year career at Gilead, Greg has taken on roles of increasing responsibility including Project Team Leader for 5 Research programs and leading 2 of those programs to IND and into Phase 1 studies. He has worked across therapeutic areas and has contributed to the discovery of 7 clinical candidates spanning Oncology, Fibrosis, HBV and Cardiovascular disease areas. Greg earned his PhD in Chemistry from University of Colorado at Boulder, and completed his postdoctoral studies at Columbia.